RESEARCHERS
 
LOG IN
SIGN-UP
SEARCH
JUMP TO ADVANCED SEARCH
                                            
Dr. Diamandis is using proteomics and mass spectrometry to discover and validate novel biomarkers for diagnosis and monitoring of cancer.
Welcome to the Genomics Sector Innovation Network (G-SIN) portal

Dr. Diamandis is using proteomics and mass spectrometry to discover and validate novel biomarkers for diagnosis and monitoring of cancer.
EXPLORE >   Researchers >  Eleftherios Diamandis
Eleftherios Diamandis |
Mount Sinai Hospital
RESEARCH
BIOGRAPHY
KEY PUBLICATIONS
INTELLECTUAL PROPERTY
Research
Dr. Diamandis’ research focuses on four areas including: proteomics, tumor markers, kallikrein biology and pathophysiology, with efforts on cancer and other diseases including neurodegeneration, inflammation and skin disorders. In terms of kallikrein biology, the laboratory has cloned numerous novel genes including those that belong to the kallikrein gene family which encode a group of related serine proteases. Dr. Diamandis is specifically interested in kallikrein gene structure and transcriptional regulation, protein function and enzymology, discovery of physiological pathways involving kallikreins, identification of physiological substrates, gene rearrangements in cancer, and the potential clinical applications of kallikreins as diagnostic and therapeutic targets. Dr. Diamandis’ research team is also working towards delineating the proteome of biological fluids and cancer cell lines to identify molecules that may represent novel cancer biomarkers for breast, ovarian, lung, prostate and other cancers. This research involves extensive use of tissue culture technologies, fractionation and purification with various chromatographic techniques and mass spectrometric analysis of fractionated proteins. The laboratory was the first to delineate the proteomes of amniotic and cervico-vaginal fluid. In the area of clinical proteomics, the research team is seeking to identify novel molecules or proteomic signatures that can be used for early detection of cancer, as well as prognosis and monitoring. Dr. Diamandis is a founding member and Principal Investigator of the Ontario Cancer Biomarker Network, a consortium which aims to discover, use and commercialize novel cancer biomarkers.
Researcher Information
Head, Clinical Biochemistry Section
Pathology and Laboratory Medicine

60 Murray Street
Suite m6-201
Toronto, Ontario
Canada M5T 3L9
Send a message
Log In to mark favourites


Biography
In 1979 Dr. Diamandis received his PhD in Analytical Chemistry and his medical degree in 1986 both from the University of Athens in Greece. Dr. Diamandis is the Head of the Clinical Biochemistry Section Pathology & Laboratory Medicine Department at Mount Sinai Hospital and Professor and Head of the Division of Clinical Biochemistry in Department of Laboratory Medicine & Pathobiology at the University of Toronto. He is also Biochemist-in-Chief in Department of Clinical Biochemistry at the University Health Network and Toronto Medical Laboratories in Toronto and the Director of the Advanced Centre for the Detection of Cancer. Dr. Diamandis has received several awards and including the Distinguished Scientist Award from the National Academy of Clinical Biochemistry in 2000 and the Miriam Reiner Award from the Capital Section of the American Association for Clinical Chemistry in 2001. In he received the Abbott Award from the International Society for Oncodevelopmental Biology and Medicine and in 2006 he was honoured with the Frey-Werle Commemorative Gold Medal from the Frey-Werle Foundation.
Researcher Information
Head, Clinical Biochemistry Section
Pathology and Laboratory Medicine

60 Murray Street
Suite m6-201
Toronto, Ontario
Canada M5T 3L9


Key Publications
Eissa A, Amodeo V, Smith CR, Diamandis EP. Kallikrein-related peptidase-8 (KLK8) is an active serine protease in human epidermis and sweat and is involved in a skin barrier proteolytic cascade. J Biol Chem. 2010 Oct 12.
Karagiannis GS, Pavlou MP, Diamandis EP. Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology. Mol Oncol. 2010 Dec;4(6):496-510.
Sardana G, Diamandis EP. The Kallikrein family of proteins as urinary biomarkers for the detection of prostate cancer. Clin Biochem. 2009 Jun 25
Cherney DZ, Konvalinka A, Zinman B, Diamandis EP, Soosaipillai A, Reich H, Lorraine J, Lai V, Scholey JW, Miller JA. Effect of protein kinase Cbeta inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study. Diabetes Care 2009 Jan;32(1):91-3.
Kuzmanov U, Jiang N, Smith CR, Soosaipillai A, Diamandis EP. Differential n-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system. Mol Cell Proteomics 2008 Dec 16.
Researcher Information
Head, Clinical Biochemistry Section
Pathology and Laboratory Medicine

60 Murray Street
Suite m6-201
Toronto, Ontario
Canada M5T 3L9


Intellectual Property

Researcher Information
Head, Clinical Biochemistry Section
Pathology and Laboratory Medicine

60 Murray Street
Suite m6-201
Toronto, Ontario
Canada M5T 3L9
YOU MAY ALSO BE INTERESTED IN:


CATEGORIES
Application Area
Human health, Instrumentation and tools
Disciplinary Focus
Clinical science, Experimental biology and chemistry
Research Paradigm
Focused-scope projects, Large-scale projects
Organism
Human
Sign-up to edit this profile
Events Jobs What is Genomics Genomics in Canada About Us Contact Us Privacy Policy Terms of Use Site-Map
© Ontario Genomics Institute, 2007-2014.